If you started semaglutide or tirzepatide and noticed more hair in the shower drain or on your pillow, you're not imagining it, and you're not alone in asking about it. GLP-1 hair loss comes up often in patient forums and in clinic waiting rooms, and it deserves a calm, evidence-based look. This post separates what people report from what clinical data actually shows, explains a likely mechanism, and gives you a practical plan for the conversation with your doctor.
Noticing more hair in the shower drain on semaglutide or tirzepatide? Here is how telogen effluvium may fit in, what the research can and cannot say, and what to check with your doctor.
Why people notice hair loss on GLP-1 medication
Hair loss rarely announces itself with a diagnosis. It usually starts with a comb that comes out fuller than usual, a thicker clump in the bathroom drain, or strands stuck to a pillowcase. Those small, everyday observations are how most people first notice a problem, and they're also why the topic spreads so quickly online. Stories pile up, and each one feels convincing.
Stories are useful for generating questions, but they can't establish cause. Many people starting a new medication are also losing weight, changing how they eat, and dealing with stress, and every one of those factors can affect hair. A forum thread can tell you that hair loss happens to people on GLP-1 drugs. It can't tell you whether the drug is the reason.
The pattern matters, and it's one of the most useful things to describe to your doctor. Diffuse shedding means hair thins evenly across the scalp, often with more fallout during brushing or washing. Localized loss means defined patches or areas where hair thins in a specific spot. A diffuse pattern points toward a body-wide trigger, while patchy loss follows a different set of causes and needs a different workup. Telling your doctor which one you see can shape the entire conversation.
Drug labels are the other place to check. Alopecia appears among the adverse events reported in some clinical trials of semaglutide and tirzepatide. The exact frequency changes between label versions, so look up the current prescribing information for your specific product rather than relying on what you read somewhere else, including this post.
Log symptoms with intensity and tie them to each dose to spot patterns.